From Raw Materials to Conjugation Sites: Advanced LC, MS and MALS Strategies for AOC Characterization and Monitoring
Advanced Analytics for Next‑Generation Protein Therapeutics
Proteins like monoclonal antibodies (mAbs) and protein conjugates promise higher efficacy and novel targets compared to traditional therapies. Given their biotherapeutic structural complexity, these molecules pose significant analytical challenges, with quality attributes like composition, aggregation, purity, and conformation affecting efficacy and toxicity.
This webinar explores the comprehensive analysis of Antibody Oligonucleotide Conjugates (AOCs) using Liquid Chromatography-Mass Spectrometry (LC-MS) and Liquid Chromatography-Multi-Angle Light Scattering (LC-MALS).
The value you’ll get from attending
- Discover methodologies for accurate pairing of technology and attribute across the product lifecycle
- Learn about recent advances, with insights into adopting advanced analytics
- Ensure novel and robust analytical capability for the analysis of bioconjugates
Who should attend?
This webinar is designed for you if you are a scientist, lab manager, director, or analyst involved in protein development, process development, or quality control of AOCs, ADCs, or other protein therapeutics.
Don't miss it!
Presenter: Samantha Ippoliti (Principal Scientist, Biologics Business, Waters Corporation)
Samantha (Sam) joined Waters (Milford, MA) in 2018 and has worked on a variety of applications for LC-MS based biopharmaceutical characterization, including peptide mapping & intact/subunit analysis, and most recently antibody-oligonucleotide conjugates (AOCs).
Sam has experience with LC-MS analysis using BioAccord, Xevo series, Synapt XS, and Cyclic IMS LC-MS instruments.
Prior to joining Waters, she was part of the LC-MS characterization group supporting a biopharmaceutical developability assessment group at Novartis in Cambridge, MA. Sam acquired a BS-MS in Chemistry from Northeastern University in 2012.
Presenter: Nick Pittman (Sr. Marketing Manager, Global Biopharma Business, Waters Corporation)
